JAZZ PHARMACEUTICALS FRANCE
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 2003-01-01
- Employees
- -
- Market Cap
- -
European VOD Registry
- Conditions
- Hepatic Veno-Occlusive Disease
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 176
- Registration Number
- NCT03032016
- Locations
- 🇫🇷
CHU d'Estaing, Clermont Ferrand, France
🇫🇷IHOP, Lyon, France
🇫🇷Hôpital d'enfants de la Timone, Mare aux Daims, France
A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy
- First Posted Date
- 2017-01-25
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 201
- Registration Number
- NCT03030599
- Locations
- 🇺🇸
SDS Clinical Trials, Inc., Orange, California, United States
🇺🇸Stanford Health Services, Stanford, California, United States
🇺🇸Fort Wayne Neurological Center, Fort Wayne, Indiana, United States
Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT02954887
- Locations
- 🇺🇸
Le Bonheur Children's Hospital, Memphis, Tennessee, United States
🇵🇱Centrum Medyczne POMOC, Łódź, Poland
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT02953548
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸The Childrens Hospital of San Antonio, San Antonio, Texas, United States
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
- Conditions
- HER2-expressing Cancers
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 279
- Registration Number
- NCT02892123
- Locations
- 🇺🇸
Hoag Family Cancer Institute, Newport Beach, California, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients
- Conditions
- Veno-occlusive Disease
- Interventions
- Other: Best Supportive Care
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 372
- Registration Number
- NCT02851407
- Locations
- 🇯🇵
Osaka City University Hospital, Osaka, Japan
🇯🇵Medical Hospital Tokyo Medical and Dental University, Tokyo, Japan
🇰🇷Severance Hospital at Yonsei University Health System, Seoul, Korea, Republic of
Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2021-01-13
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT02806908
- Locations
- 🇳🇱
Maastricht University, Maastricht, Limburg, Netherlands
Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA
- Conditions
- Excessive SleepinessObstructive Sleep Apnea
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2021-01-14
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT02806895
- Locations
- 🇳🇱
Maastricht University, Maastricht, Limburg, Netherlands
A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy
- Conditions
- Narcolepsy
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 1500
- Registration Number
- NCT02769780
- Locations
- 🇺🇸
Jazz Pharmaceuticals, Palo Alto, California, United States
A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 35
- Registration Number
- NCT02607891
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇳🇱SEIN - Epilepsy Institute in the Netherlands Foundation, Zwolle, Netherlands
🇪🇸Hospital Ruber Internacional, Madrid, Spain